Marina Chiara Garassino to Angiogenesis Inhibitors
This is a "connection" page, showing publications Marina Chiara Garassino has written about Angiogenesis Inhibitors.
Connection Strength
0.526
-
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2021 10; 22(10):1438-1447.
Score: 0.169
-
Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. Lung Cancer. 2018 06; 120:62-69.
Score: 0.133
-
Is the chemotherapy era in advanced non-small cell lung cancer really over? Maybe not yet. Tumori. 2016 Jun 02; 2016(3):223-5.
Score: 0.116
-
Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. Dig Liver Dis. 2011 Apr; 43(4):286-94.
Score: 0.080
-
Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy? Tumori. 2016 Jan-Feb; 102(1):18-30.
Score: 0.028